Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of abemaciclib plus adjuvant endocrine therapy after completion of HER2-directed adjuvant treatment in high-risk HR-positive/HER2-positive early breast cancer
MOH_2021-05-11_009924Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib plus endocrine therapy with Placebo plus endocrine therapy (2 arms). Started Apr 2021; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2021-05-11_009924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-11_009924.